Tag Archives: ecyt

Merck, Endocyte Stop Trial Of Ovarian Cancer Drug

Biotech firm Endocyte (ECYT) and its big-pharma partner Merck (MRK) pulled the plug on their ovarian-cancer treatment Vynfinit Friday, sending both stocks tumbling on the stock market today. The companies said that the Data Safety Monitoring Board’s interim analysis of the phase-three trial of Vynfinit, known generically as vintafolide, was not showing any improvement in patients’ progression-free survival, so it said the trial should be stopped.

Endocyte Price Targets Hiked On Cancer Drug News

Biotech Endocyte (ECYT) got a couple of hefty price-target increases from analysts Tuesday in the wake of last week’s positive Vynfinit news, sending the stock up about 4% in morning trading on the stock market today, near 28.30. Wedbush analyst Gregory Wade lifted his target to 65 from 23, giving room for substantial upside even after Friday’s more than 100% intraday jump to a record high of 33.70. He estimates $430 million in peak annual sales

Endocyte, Merck Cancer Drug Scores Twice

Biotech Endocyte (ECYT) and its big-pharma partner Merck (MRK) got a double dose of good news on their cancer drug vintafolide Friday, more than doubling Endocyte’s stock on the stock market today. First, the European Medicines Agency’s advisory committee recommended conditional approval of vintafolide, branded Vynfinit, along with two companion imaging agents for treatment of ovarian cancer. The imaging agents are used to identify cancers that